Analysts’ Weekly Ratings Changes for Vanda Pharmaceuticals (VNDA)

A number of firms have modified their ratings and price targets on shares of Vanda Pharmaceuticals (NASDAQ: VNDA) recently:

• 1/28/2025 – Vanda Pharmaceuticals is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 1/28/2025 – Vanda Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
• 1/21/2025 – Vanda Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
• 1/20/2025 – Vanda Pharmaceuticals is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 1/12/2025 – Vanda Pharmaceuticals is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 1/4/2025 – Vanda Pharmaceuticals is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/27/2024 – Vanda Pharmaceuticals is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/23/2024 – Vanda Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
• 12/19/2024 – Vanda Pharmaceuticals is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/11/2024 – Vanda Pharmaceuticals is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/3/2024 – Vanda Pharmaceuticals is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

Vanda Pharmaceuticals Price Performance

VNDA stock opened at $4.58 on Friday. The business has a 50-day moving average price of $4.72 and a 200 day moving average price of $4.98. The company has a market capitalization of $267.06 million, a P/E ratio of -16.36 and a beta of 0.77. Vanda Pharmaceuticals Inc. has a 1-year low of $3.46 and a 1-year high of $6.75.

Insider Activity at Vanda Pharmaceuticals

In related news, Director Stephen Ray Mitchell sold 5,000 shares of Vanda Pharmaceuticals stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $5.17, for a total value of $25,850.00. Following the completion of the sale, the director now directly owns 44,857 shares in the company, valued at $231,910.69. The trade was a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 8.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Vanda Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. ORG Wealth Partners LLC purchased a new position in Vanda Pharmaceuticals in the third quarter valued at about $40,000. China Universal Asset Management Co. Ltd. grew its stake in Vanda Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 4,374 shares during the last quarter. Intech Investment Management LLC purchased a new position in Vanda Pharmaceuticals in the third quarter valued at about $84,000. SG Americas Securities LLC grew its stake in Vanda Pharmaceuticals by 88.5% in the third quarter. SG Americas Securities LLC now owns 20,402 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 9,580 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in Vanda Pharmaceuticals in the third quarter valued at about $143,000. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.